Determining the value contribution of emicizumab (Hemlibra (R)) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis

Autor: Alvarez-Roman, MT, Cuervo-Arango, I, Perez-Santamarina, R, Poveda, JL, Romero, JA, Santamaria, A, Trillo-Mata, JL, Tort, M, Badia, X

Publikováno v: GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

Patients with moderate to severe haemophilia A are at a higher risk of developing FVIII inhibitors that require the use of more costly and less effective treatments. The objective of this study was to determine the value of emicizumab for the prophyl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::f103a2417366d1b074b2f6ada81a5145
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=11236

POSC33 Value Contribution of Filgotinib for the Treatment of Moderate to Severe Rheumatoid Arthritis Using Multi-Criteria Decision Analysis (MCDA)

Autor: Arraiza, A, Casaus, E, Fernández, MÁ, González, C, López, A, Poveda, JL, Pablo, Q, Trillo, JL, Cuervo-Arango, I, Subirán, R, Badia, X

Publikováno v: In Value in Health January 2022 25(1) Supplement:S39-S39

PMS17 A Budget IMPACT Analysis of Filgotinib for the Treatment of Adult Patients with Moderate to Severe Rheumatoid Arthritis – a Spanish Healthcare Perspective

Autor: Brown, T., Sadler, S., Cadwell, K., Jacob, I., Cuervo-Arango, I., Lu, X.

Publikováno v: In Value in Health December 2020 23 Supplement 2:S595-S595

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.